Increased vitamin B12 in heart failure with reduced ejection fraction: A novel marker of disease severity and mortality

Basit Öğe Kaydı
dc.authoridERBAY, ILKE/0000-0002-6817-4686
dc.contributor.authorErbay, Ilke
dc.contributor.authorDemirkan, Burcu
dc.contributor.authorAkin, Yesim
dc.contributor.authorBalci, Gulcihan Kevser
dc.date.accessioned2024-09-29T16:09:35Z
dc.date.available2024-09-29T16:09:35Z
dc.date.issued2024
dc.departmentKarabük Üniversitesien_US
dc.description.abstractAim: The relationship between elevated vitamin B12 levels and liver damage is well -established, but its association with the severity of heart failure (HF) remains unclear. This study aimed to investigate the prognostic importance of vitamin B12 levels according to disease severity in HF patients with reduced left ventricular ejection fraction (HFrEF). Material and Methods: Two hundred and three consecutive patients with HFrEF were enrolled in this study. Patients were divided into advanced and nonadvanced HF groups based on specific criteria and the primary endpoint was all -cause mortality, which was prospectively assessed. Cox proportional hazards regression analyses were conducted to identify independent predictors of mortality. Results: Of the study patients, 75 (36.9%) had advanced, while 128 (63.1%) had non -advanced HF. The advanced group had significantly higher serum vitamin B12 levels compared to the non -advanced group (p<0.001). Serum vitamin B12 level of > 707.8 pg/mL had a sensitivity of 78.3% and specificity of 76.1% in predicting all -cause mortality (area under the curve=0.863, 95% CI 0.806-0.920, p<0.001). Kaplan -Meier analysis demonstrated that patients with vitamin B12 levels > 707.8 pg/mL had significantly lower survival rates (p < 0.001). In Cox regression analysis, vitamin B12 emerged as an independent predictor of death. Discussion: Elevated serum vitamin B12 levels in HFrEF patients are associated with advanced HF, increased ALT and GGT levels, indicating a cardiohepatic syndrome, and independently predict higher all -cause mortality risk.en_US
dc.identifier.doi10.4328/ACAM.21994
dc.identifier.endpage382en_US
dc.identifier.issn2667-663X
dc.identifier.issue6en_US
dc.identifier.startpage377en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.21994
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7642
dc.identifier.volume15en_US
dc.identifier.wosWOS:001244769300002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHeart Failureen_US
dc.subjectVitamin B12en_US
dc.subjectHepatic Congestionen_US
dc.subjectMortalityen_US
dc.subjectBiomarkeren_US
dc.titleIncreased vitamin B12 in heart failure with reduced ejection fraction: A novel marker of disease severity and mortalityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize